Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Premier Biomedical Inc. Stories

2013-06-11 08:31:17

Protocols for CRADA Implementation Approved ST. PETERSBURG, Fla., June 11, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) (http://www.premierbiomedical.com) today announced that a Cooperative Research and Development Agreement (CRADA) with William Beaumont Army Medical Center (WBAMC) (http://www.wbamc.amedd.army.mil) located at Fort Bliss, in El Paso, Texas has been signed and approved by the US Army Clinical Investigation Regulatory Office (CIRO) for implementation....

2013-04-30 08:34:20

ST. PETERSBURG, Fla., April 30, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced that President and Chief Executive Officer William Hartman was recently interviewed by The Wall Street Transcript (TWST), an independent investment publication of interviews with company CEOs, money managers, and Wall Street analysts. The Bill Hartman interview appears in the publication's Biotechnology and Pharmaceuticals Report available by calling (212) 952-7433 or via The Wall...

2013-03-28 08:28:22

ST. PETERSBURG, Fla., March 28, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) (http://www.premierbiomedical.com/) today announced that it has advanced its pre-clinical testing of its extracorporeal-treatment methodology for use against cancer from test tubes to mice. These tests are being conducted by academic researchers at The University of Texas at El Paso (UTEP) under direction of Dr. Mitchell S. Felder of Premier Biomedical (PBI). PBI and UTEP are ahead of schedule by...

2013-02-21 08:31:32

ST. PETERSBURG, Fla., Feb. 21, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced that it has acquired exclusive rights to a provisional patent application against Retinitis Pigmentosa. This exclusive intellectual property right, a result of Premier's long-standing licensing agreements, proposes a novel method for treating the degenerative eye disease via the targeted removal of specified target antigens. This is the latest of many proposed applications of Premier...

2013-01-09 08:26:47

ST. PETERSBURG, Fla., Jan. 9, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced a proposed novel therapy for the treatment of the currently untreatable neurological condition Neurofibromatosis. The key to this breakthrough is the targeted application of the Felder Doctrine(TM), which calls for "physically removing the pathophysiologic basis of the disease." The painful and often fatal disease Neurofibromatosis, which is characterized by the growth of tumors around...

2012-12-18 08:27:50

ST. PETERSBURG, Fla., Dec. 18, 2012 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced a major achievement in its effort to develop a therapy for suicidal ideation and clinical depression. Premier Biomedical, Inc., which to date has achieved promising and innovative successes against cancer without application of any medication, was successful in removing the majority of target antigens associated with these two depressive disorder diseases from a heterogeneous mixture in...

2012-12-05 08:26:36

ST. PETERSBURG, Fla., Dec. 5, 2012 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced successful advances in its cancer-focused research. Researchers successfully killed a cancer tumor in a test tube by simply removing crucial molecular compounds necessary for the cancer's development. This was accomplished utilizing the Felder Doctrine(TM): "Physically remove the pathophysiologic basis of the disease." Dr. Mitchell S. Felder, Chairman of Premier Biomedical, Inc.'s...